The acute response of strength training for young people with congenital heart disease Circulatory System
Conditions
Interventions
This single-centre, quasi-experimental interventional study compares adolescents and young adults with congenital heart disease (ConHD) with matched healthy controls during a single supervised progres
allocation is non-random by disease status (ConHD vs healthy), there is no allocation concealment or blinding, and the control group consists of healthy peers undertaking the same protocol (no placebo
safety procedures include stopping if SpO2 85% HRmax, or symptoms/arrhythmia, with AED/first-aid available on site. All procedures are conducted at the University of Exeter CHERC laboratory and St Lu
Sponsors
University of Exeter
Eligibility
Sex/Gender
All
Age
15 Years to 24 Years
Inclusion criteria
Inclusion criteria: For young people with ConHD: 1. Young people aged 15 to 24 years 2. People diagnosed with different types of ConHD 3. All participants with ConHD are New York Heart Association (NYHA) class I (patients will not experience discomfort in normal daily activities) to class II (patients will feel some fatigue, shortness of breath, palpitations, and other symptoms, but will not be affected during the resting state), the New York NYHA ratings for people with ConHD. For healthy young people: 1. The age, gender, and strength training experience of the healthy participants will be matched to those with ConHD 2. The absence of cardiovascular and respiratory diseases 3. The ability to perform moderate to vigorous activity (70% - 85% 1 RM), and adherence to verbal commands related to experimental procedures. Participants will complete a Physical Activity Readiness Questionnaire to assess their health status and exercise adaptability before the experiment
Exclusion criteria
Exclusion criteria: For young people with ConHD: 1. Personal history of documented life-threatening arrhythmias 2. Inability or contraindication to perform required physical activity 3. Significant depression of left or right ventricle function (subjective or left ventricular ejection fraction < 54%) 4. Severe aortic stenosis or severe left ventricular outflow tract obstruction 5. Presence of significant non-cardiac causes that impair mobility (including respiratory, neurological, or musculoskeletal) 6. Physical inability to perform a cardiopulmonary exercise test (CPET), participation in other exercise training programmes, and contra-indications for exercise (arrhythmias)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Peak knee extensor torque (Nm) is measured using a Biodex System 3 isokinetic dynamometer at 60°/s (mean of 3 trials) at Visit-1 baseline and Visit-2 pre-training and ~10 min post-training 2. Knee extensor fatigue index (%) is measured using a Biodex isokinetic dynamometer at 180°/s over 20 continuous maximal repetitions (fatigue index from the mean of the first 5 vs last 5 reps) at Visit-1 baseline and Visit-2 pre-training and ~10 min post-training 3. Maximal handgrip strength (N) is measured using a hand dynamometer (dominant hand, 3 trials separated by 1 min; mean of 3) at Visit-1 baseline and Visit-2 pre-training and ~10 min post-training | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Systolic/diastolic blood pressure (mmHg) is measured using an automated sphygmomanometer (Omron M6) at Visit-1 baseline and at each set and at session end during Visit-2 2. Heart rate (bpm) is measured using a heart-rate monitor at Visit-2 before, continuously during, and after the session 3. Peripheral oxygen saturation (SpO2, %) is measured using a fingertip pulse oximeter (Nonin Onyx Vantage) at Visit-2 before, continuously during, and after the session 4. Rating of Perceived Exertion (RPE, 0–10) is measured using the Borg CR10 scale at the rest period after each exercise during Visit-2 5. Exercise enjoyment (PACES, 4-item) is measured using the PACES questionnaire at the end of each set during Visit-2 6. Affective valence (Feeling Scale, -5 to +5) is measured using the Feeling Scale at the end of each exercise during Visit-2 7. Delayed-onset muscle soreness (DOMS, 0–10) is measured using a visual analogue scale (VAS 0–100 mm converted to 0–10) at Visit-2 pre-training (baseline) and once daily on Days 1–3 after Visit-2 | — |
Countries
England, United Kingdom
Contacts
Public ContactKunyu Hao
Outcome results
None listed